Post Marketing Surveillance Study To Observe Safety And Efficacy Of Champix® Tablets
NCT00483002
Last updated date
ABOUT THIS STUDY
To monitor use in real practice including safety and efficacy of Champix tablets 0.5mg, 1mg
medication for 12 weeks in smokers
FOR MORE INFORMATION
Contact a representative by phone, email, or visiting the study website. Please see the references below:
By phone
Pfizer Clinical Trials Contact Center
1-800-718-1021
Eligibility Criteria
condition
Smoking Cessation
Sex
Females and Males
Age
18 + years
Inclusion Criteria
Show details
- Subjects selected for this study are those who would have been prescribed Champix tablets by the physician according to the subject's condition in usual clinical practice.
Exclusion Criteria
Show details
- None
NEED INFO?
Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative
TRY A NEW SEARCH
Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.
Based on your search, you may also be interested in
Smoking CessationEffectiveness of Combination Varenicline and Oral Nicotine Replacement Therapy (COMBO)
NCT03722966
- Oklahoma City, Oklahoma
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Smoking CessationMessage Priming and Enrollment in, and Response to, a Smoking Cessation Program: A Pilot Study
NCT00596882
- Philadelphia, Pennsylvania
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Smoking CessationAn Alternative Dosing Schedule of Varenicline for Smoking Cessation
NCT00835900
- Buffalo, New York
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Smoking CessationVarenicline In-Patient Study
NCT01413516
- Stanford, California
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Advanced Information
Descriptive Information | ||||
---|---|---|---|---|
Brief Title | Post Marketing Surveillance Study To Observe Safety And Efficacy Of Champix® Tablets | |||
Official Title | Post Marketing Surveillance Study To Observe Safety And Efficacy Of Champix® Tablets | |||
Brief Summary | To monitor use in real practice including safety and efficacy of Champix tablets 0.5mg, 1mg medication for 12 weeks in smokers | |||
Detailed Description | No sampling method will be applied to this study. | |||
Study Type | Observational | |||
Study Design | Observational Model: Case-Only Time Perspective: Prospective | |||
Target Follow-Up Duration | Not Provided | |||
Biospecimen | Not Provided | |||
Sampling Method | Non-Probability Sample | |||
Study Population | Healthy smokers | |||
Condition | Smoking Cessation | |||
Intervention | Drug: varenicline
As prescribed by physician in usual clinical practice. Other Name: Champix, Chantix, CP-526,555 | |||
Study Groups/Cohorts | Healthy smokers
Intervention: Drug: varenicline | |||
Publications * | Not Provided | |||
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline. | ||||
Recruitment Information | ||||
Recruitment Status | Completed | |||
Actual Enrollment | 3719 | |||
Original Enrollment | 4500 | |||
Actual Study Completion Date | May 2011 | |||
Actual Primary Completion Date | May 2011 (Final data collection date for primary outcome measure) | |||
Eligibility Criteria | Inclusion Criteria:
Exclusion Criteria:
| |||
Sex/Gender |
| |||
Ages | 18 Years and older (Adult, Older Adult) | |||
Accepts Healthy Volunteers | No | |||
Contacts | Contact information is only displayed when the study is recruiting subjects | |||
Listed Location Countries | Not Provided | |||
Removed Location Countries | ||||
Administrative Information | ||||
NCT Number | NCT00483002 | |||
Other Study ID Numbers | A3051083 | |||
Has Data Monitoring Committee | Yes | |||
U.S. FDA-regulated Product | Not Provided | |||
IPD Sharing Statement | Not Provided | |||
Responsible Party | Pfizer | |||
Study Sponsor | Pfizer | |||
Collaborators | Not Provided | |||
Investigators |
| |||
PRS Account | Pfizer | |||
Verification Date | April 2012 |